InventisBio

2024 World Lung Cancer Conference (WCLC) | Latest Progress of Garsorasib (D-1553) in Treating KRAS G12C-Mutant Non-Small Cell Lung Cancer: Phase 2 Study Updates

InventisBio announces the development of its TYK2 JH2 inhibitor D-2570 (Nomelcitin).

InventisBio’s KRAS G12C inhibitor Anfangning (Garsorasib, D-1553) receives market authorization from China’s NMPA for treating advanced non-small cell lung cancer.

InventisBio’s D1553-102 study is China’s first approved phase 2 pivotal trial for KRAS G12C inhibitor in lung cancer, targeting late-stage or metastatic NSCLC patients.

Building 63 1000 Zhangheng Road, Pudong, Shanghai 201203 Tel: +86-(0)21-5077-8527

InventisBio’s tyrosine kinase 2 (TYK2) inhibitor **nomelcitinib** achieves success in a pivotal Phase III trial for psoriasis treatment. The drug advances toward market entry amid growing competition in the TYK2 inhibitor space. The Shanghai-based biotech’s milestone follows rising demand for novel psoriasis therapies targeting the same pathway.

Nov 2026Clinical Trials ArenaNews article

InventisBio reports that its oral TYK2 inhibitor **nomelcitinib** achieves Phase III success in treating moderate-to-severe plaque psoriasis. The milestone positions the drug as a competitive candidate in the expanding market of oral therapies for the condition. The company, listed on the Shanghai Stock Exchange, highlights the potential of nomelcitinib in addressing unmet needs in psoriasis treatment.

Nov 2026thepharmaletter.comNews article

InventisBio’s TYK2 inhibitor **nomelcitinib** meets the primary endpoint in a phase 3 trial for psoriasis, demonstrating efficacy comparable to existing treatments. The trial results position the drug as a potential rival in the competitive psoriasis therapy market. InventisBio’s achievement follows ongoing efforts to advance nomelcitinib as a differentiated oral option for inflammatory skin conditions.

Nov 2026Fierce BiotechNews article

InventisBio’s TYK2 inhibitor **nomelcitinib** meets primary and key secondary endpoints in a Phase III trial for moderate-to-severe plaque psoriasis, showing statistically significant efficacy and safety over placebo. The drug, a selective JH2 inhibitor (D-2570), achieves clinically meaningful results in the registrational study, advancing its development as a potential psoriasis treatment. The topline data highlight its potential as a novel therapeutic option in dermatology.

Nov 2026PR NewswireNews article